VAXELIS Market Drug Insight

“VAXELIS Market Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about VAXELIS for pertussis in the six major markets. A detailed picture of the VAXELIS for pertussis in the 6MM, i.e., United States and EU5 (Germany, France, Italy, Spain, and the United Kingdom) for the study period 2019 –2032 is provided in this report along with a detailed description of the VAXELIS for pertussis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAXELIS market forecast analysis for pertussis in the 6MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in pertussis.

Drug Summary

VAXELIS is a PR5i hexavalent combination vaccine indicated for active immunization to prevent pertussis (whooping cough), diphtheria, tetanus, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.

VAXELIS was developed as part of a US-based partnership established in 1991 between Merck and Sanofi Pasteur and draws upon both company's experience in the development, manufacturing, and marketing of individual and combination vaccines. It includes antigens for pertussis (whooping cough), diphtheria, tetanus, and poliomyelitis from Sanofi Pasteur and antigens for Haemophilus influenzae type b and hepatitis B from Merck.

VAXELIS is administered as a three-dose immunization series of a 0.5 mL intramuscular injection at 2, 4, and 6 months of age. The first dose may be given as early as 6 weeks of age, and a 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis, so an additional dose of pertussis-containing vaccine is needed to complete the primary series. It is recommended that children who have received a 3-dose series of VAXELIS should complete the primary and pertussis vaccination series with Pentacel, Quadracel, or Daptacel.

VAXELIS was approved by the FDA in December 2018, becoming the first hexavalent vaccine to be approved in the US, and it became commercially available in US in June 2021. It was approved in 2016 by the EMA and was commercially available in 2017.

MCM Vaccine has developed a 6-in-1 vaccine indicated for the primary and booster vaccinations of infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis and diseases caused by Haemophilus influenzae type b. 

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the VAXELIS description, mechanism of action, dosage and administration, research and development activities in pertussis.
•  Elaborated details on VAXELIS regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the VAXELIS research and development activities in pertussis across the United States and Europe.
•  The report also covers the patents information with expiry timeline around VAXELIS.
•  The report contains forecasted sales of VAXELIS for pertussis till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for pertussis.
•  The report also features the SWOT analysis with analyst views for VAXELIS in pertussis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VAXELIS Analytical Perspective by DelveInsight

•  In-depth VAXELIS Market Assessment

This report provides a detailed market assessment of VAXELIS for pertussis in the seven major markets, i.e., United States and EU5 (Germany, France, Italy, Spain, and the United Kingdom). This segment of the report provides forecasted sales data from 2022 to 2032.

•  VAXELIS Clinical Assessment

The report provides the clinical trials information of VAXELIS for pertussis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for pertussis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAXELIS dominance.
•  Other emerging products for pertussis are expected to give tough market competition to VAXELIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAXELIS in pertussis.
•  Our in-depth analysis of the forecasted sales data of VAXELIS from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VAXELIS in pertussis.

Key Questions

•  What is the product type, route of administration and mechanism of action of VAXELIS?
•  What is the clinical trial status of the study related to VAXELIS in pertussis and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAXELIS development?
•  What are the key designations that have been granted to VAXELIS for pertussis?
•  What is the forecasted market scenario of VAXELIS for pertussis?
•  What are the forecasted sales of VAXELIS in the seven major countries, including the United States and Europe including Germany, France, Italy, Spain, and the United Kingdom? 
•  What are the other emerging products available and how are these giving competition to VAXELIS for pertussis?
•  Which are the late-stage emerging therapies under development for the treatment of pertussis?